ANTI-INFLAMMATORY DRUGS MARKET ANALYSIS

Regional Analysis

To learn more about this report, request sample copy

North America dominates the global anti-inflammatory drugs market with an estimated market share of 35.2% in 2024. With presence of leading pharmaceutical companies based in countries like the U.S. and Canada, the region accounts for the largest share of research and development activities. Many new drug formulations are launched and approved in the region first before being made available in other parts of the world. Furthermore, countries in North America have well-established healthcare systems that provide affordable access to innovative drugs, thus, boosting higher consumption. The on-going developments in biosimilars by major players enable cost savings, which can increase patients pool undergoing treatment over the coming years.

Asia Pacific emerges as fastest-growing market for anti-inflammatory drugs. Several economic and healthcare industry have contributed to the rapid expansion.. Countries like India, China, South Korea, and Japan are prioritizing healthcare spending to address the rising incidence of chronic diseases. This has encouraged both domestic and multinational companies to expand their presence through manufacturing and distribution networks across Asia Pacific. Rising disposable incomes allows more patients in the middle-income Asian countries to opt for branded anti-inflammatory drugs over cheap generics. While import dependence remains high currently, local drug makers are investing aggressively into R&D to develop complex anti-inflammatory drugs indigenously.